CRISPR-Based Approaches for Gene Regulation in Non-Model Bacteria
TL;DR: The challenges that contribute to the slower creation of CRISPRi/a tools in diverse, non-model bacteria are discussed and the current state of these approaches across bacterial phyla is summarized.
read more
Abstract: CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) have become ubiquitous approaches to control gene expression in bacteria due to their simple design and effectiveness. By regulating transcription of a target gene(s), CRISPRi/a can dynamically engineer cellular metabolism, implement transcriptional regulation circuitry, or elucidate genotype-phenotype relationships from smaller targeted libraries up to whole genome-wide libraries. While CRISPRi/a has been primarily established in the model bacteria Escherichia coli and Bacillus subtilis, a growing numbering of studies have demonstrated the extension of these tools to other species of bacteria (here broadly referred to as non-model bacteria). In this mini-review, we discuss the challenges that contribute to the slower creation of CRISPRi/a tools in diverse, non-model bacteria and summarize the current state of these approaches across bacterial phyla. We find that despite the potential difficulties in establishing novel CRISPRi/a in non-model microbes, over 190 recent examples across eight bacterial phyla have been reported in the literature. Most studies have focused on tool development or used these CRISPRi/a approaches to interrogate gene function, with fewer examples applying CRISPRi/a gene regulation for metabolic engineering or high-throughput screens and selections. To date, most CRISPRi/a reports have been developed for common strains of non-model bacterial species, suggesting barriers remain to establish these genetic tools in undomesticated bacteria. More efficient and generalizable methods will help realize the immense potential of programmable CRISPR-based transcriptional control in diverse bacteria.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Emergent CRISPR-Cas-based technologies for engineering non-model bacteria.
TL;DR: In this paper , the authors summarize the recent trends in engineering non-model microbes using CRISPR-Cas technologies, discussing their potential in supporting cell factory design towards biotechnological applications.
32
Bacterial genome engineering using CRISPR-associated transposases.
Diego R. Gelsinger,Phuc Leo H. Vo,Sanne E. Klompe,Carlotta Ronda,Harris H Wang,Samuel H. Sternberg +5 more
TL;DR: A detailed protocol for engineering bacterial genomes using CRISPR-associated transposase (CAST) systems, including guidelines on the available vectors, customization of guide RNAs and DNA payloads, selection of common delivery methods, and genotypic analysis of integration events.
9
Cas9-mediated endogenous plasmid loss in Borrelia burgdorferi
TL;DR: It is shown that targeting wild-type Cas9 to several loci on the endogenous plasmids lp25 or lp28-1 of the B. burgdorferi type strain B31 results in sgRNA-specific plasmid loss even when homologous sequences (i.e., potential sequence donors for DNA recombination) are present nearby.
4
An efficient <i>in vivo</i> -inducible CRISPR interference system for group A <i>Streptococcus</i> genetic analysis and pathogenesis studies
Elisabet Bjånes,Alexandra Stream,Axel B. Janssen,Paddy S. Gibson,Afonso M. Bravo,Samira Dahesh,Jonathon L. Baker,Andrew Varble,Victor Nizet,Jan‐Willem Veening +9 more
TL;DR: Researchers developed a doxycycline-inducible CRISPR interference system for group A Streptococcus genetic analysis and pathogenesis studies, enabling efficient gene repression and demonstrating its functionality in vitro and in vivo, with potential applications in vaccine development and antibiotic target discovery.
4
Bacterial genome engineering using CRISPR RNA-guided transposases
Diego R. Gelsinger,Phuc Leo H. Vo,Sanne E. Klompe,Carlotta Ronda,Harris H. Wang,Samuel H. Sternberg +5 more
TL;DR: In this paper , a detailed protocol for engineering bacterial genomes using CAST systems, including guidelines on the available homologs and vectors, customization of guide RNAs and DNA payloads, selection of common delivery methods, and genotypic analysis of integration events.
References
CRISPR interference (CRISPRi) as transcriptional repression tool for Hungateiclostridium thermocellum DSM 1313
TL;DR: The CRISPRi approach for H. thermocellum to downregulate metabolic genes can be used for remodelling of metabolic pathways without the requisite for genome engineering.
CRISPRi based system for enhancing 1-butanol production in engineered Klebsiella pneumoniae
TL;DR: The results show that CRISPRi is a feasible method to manipulate genes in Klebsiella pneumoniae and reveal the relationship between 1-butanol synthesis and other metabolic pathways.
Transcriptomic Changes in Response to Putrescine Production in Metabolically Engineered Corynebacterium glutamicum.
Zhen Li,Jian-Zhong Liu +1 more
TL;DR: The transcriptional levels of genes involved in ornithine biosynthesis and NADPH-forming related enzymes were significantly upregulated in the putrescine producing C. glutamicum strain PUT-ALE, and some genetic modification strategies to further improve putresCine production were provided.
Characterizing a thermostable Cas9 for bacterial genome editing and silencing
Ioannis Mougiakos,Prarthana Mohanraju,Elleke Fenna Bosma,Elleke Fenna Bosma,Valentijn Vrouwe,Max Finger Bou,Mihris Ibnu Saleem Naduthodi,Alex Gussak,Rudolf B. L. Brinkman,Richard van Kranenburg,John van der Oost +10 more
TL;DR: ThermoCas9 is identified and characterized from the thermophilic bacterium Geobacillus thermodenitrificans T12, which is functional from 20°C to 70°C and established a Cas9-based bacterial genome editing and silencing tool with a broad temperature range.
From substrate to fragments to inhibitor activein vivoagainstStaphylococcus aureus.
Muriel Gelin,Julie Paoletti,Nahori,Valérie Huteau,C. Leseigneur,G. Jouvion,Laurence Dugué,D. Clement,Jean-Luc Pons,Liliane Assairi,Sylvie Pochet,Gilles Labesse,Olivier Dussurget +12 more
TL;DR: Novel targets and innovative strategies are urgently needed to generate pathbreaking drug compounds to address the growing threat of antibiotic resistance.